MX2021014497A - Peptidos. - Google Patents
Peptidos.Info
- Publication number
- MX2021014497A MX2021014497A MX2021014497A MX2021014497A MX2021014497A MX 2021014497 A MX2021014497 A MX 2021014497A MX 2021014497 A MX2021014497 A MX 2021014497A MX 2021014497 A MX2021014497 A MX 2021014497A MX 2021014497 A MX2021014497 A MX 2021014497A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acids
- peptide
- positions
- fragment
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000008300 Mutant Proteins Human genes 0.000 abstract 1
- 108010021466 Mutant Proteins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000037433 frameshift Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describe un péptido que comprende un fragmento de la SEC ID NO: 2 o la SEC ID NO: 8. El fragmento comprende al menos 8 aminoácidos consecutivos de la SEC ID NO: 8, incluyendo al menos una de las posiciones 121 y 135 de la SEC ID NO: 8. Alternativamente, el fragmento comprende las posiciones 6 a 13 de la SEC ID NO: 3 y el péptido comprende no más de 21 aminoácidos, el fragmento comprende las posiciones 7 a 22 de la SEC ID NO: 3 y el péptido comprende no más de 40 aminoácidos, o el fragmento comprende las posiciones 18 a 33 de la SEC ID NO: 3, y el péptido comprende no más de 33 aminoácidos. Alternativamente, el fragmento comprende la secuencia de aminoácidos de la SEC ID NO: 29, y el péptido comprende no más de 21 aminoácidos y es para su uso en el tratamiento y/o profilaxis del cáncer. El péptido es capaz de inducir una respuesta inmunitaria contra una proteína mutante con desplazamiento del marco de lectura de -1a de TGFßR2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19177444 | 2019-05-29 | ||
| PCT/EP2020/064893 WO2020239937A1 (en) | 2019-05-29 | 2020-05-28 | Peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014497A true MX2021014497A (es) | 2022-02-11 |
Family
ID=66677029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014497A MX2021014497A (es) | 2019-05-29 | 2020-05-28 | Peptidos. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220213170A1 (es) |
| EP (2) | EP4276463A3 (es) |
| JP (1) | JP2022535784A (es) |
| KR (1) | KR20220012938A (es) |
| CN (1) | CN113891723A (es) |
| AU (1) | AU2020281912A1 (es) |
| BR (1) | BR112021023957A2 (es) |
| CA (1) | CA3141951A1 (es) |
| CO (1) | CO2021017664A2 (es) |
| DK (1) | DK3840767T3 (es) |
| ES (1) | ES2970223T3 (es) |
| FI (1) | FI3840767T3 (es) |
| HR (1) | HRP20240017T1 (es) |
| IL (1) | IL288412A (es) |
| LT (1) | LT3840767T (es) |
| MX (1) | MX2021014497A (es) |
| PL (1) | PL3840767T3 (es) |
| PT (1) | PT3840767T (es) |
| SG (1) | SG11202113125QA (es) |
| SI (1) | SI3840767T1 (es) |
| WO (1) | WO2020239937A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4157335A2 (en) | 2020-05-28 | 2023-04-05 | Hubro Therapeutics AS | A peptide cocktail |
| EP4367260A1 (en) | 2021-07-09 | 2024-05-15 | Hubro Therapeutics AS | A primer |
| EP4223782A1 (en) * | 2022-02-07 | 2023-08-09 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Novel t cell receptors and immune therapy using the same for the treatment of cancer |
| WO2024052542A2 (en) | 2022-09-09 | 2024-03-14 | Hubro Therapeutics As | A peptide cocktail |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO315238B1 (no) | 1998-05-08 | 2003-08-04 | Gemvax As | Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy |
| AU2003232485A1 (en) | 2002-04-18 | 2003-10-27 | Mtm Laboratories Ag | Neopeptides and methods useful for detection and treatment of cancer |
| ATE439383T1 (de) * | 2005-09-20 | 2009-08-15 | Peter Jon Nelson | Gewebeinhibitor für metalloproteinasen (timp) gebunden an ein glycosylphosphatidylinositol (gpi-) anker zur behandlung von krebs |
| KR20130043627A (ko) * | 2010-04-09 | 2013-04-30 | 온코세라피 사이언스 가부시키가이샤 | Cdca5 펩티드 및 이를 포함한 백신 |
| CA2798988C (en) * | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
| US20200188496A1 (en) * | 2017-06-02 | 2020-06-18 | Arizona Board Of Regents On Behalf Of Arizona State University | Universal cancer vaccines and methods of making and using same |
-
2020
- 2020-05-28 JP JP2021571354A patent/JP2022535784A/ja active Pending
- 2020-05-28 WO PCT/EP2020/064893 patent/WO2020239937A1/en unknown
- 2020-05-28 BR BR112021023957A patent/BR112021023957A2/pt unknown
- 2020-05-28 FI FIEP20728497.7T patent/FI3840767T3/fi active
- 2020-05-28 PT PT207284977T patent/PT3840767T/pt unknown
- 2020-05-28 EP EP23185952.1A patent/EP4276463A3/en active Pending
- 2020-05-28 DK DK20728497.7T patent/DK3840767T3/da active
- 2020-05-28 AU AU2020281912A patent/AU2020281912A1/en active Pending
- 2020-05-28 HR HRP20240017TT patent/HRP20240017T1/hr unknown
- 2020-05-28 KR KR1020217042578A patent/KR20220012938A/ko unknown
- 2020-05-28 CN CN202080039516.0A patent/CN113891723A/zh active Pending
- 2020-05-28 US US17/614,272 patent/US20220213170A1/en active Pending
- 2020-05-28 EP EP20728497.7A patent/EP3840767B1/en active Active
- 2020-05-28 CA CA3141951A patent/CA3141951A1/en active Pending
- 2020-05-28 LT LTEPPCT/EP2020/064893T patent/LT3840767T/lt unknown
- 2020-05-28 ES ES20728497T patent/ES2970223T3/es active Active
- 2020-05-28 PL PL20728497.7T patent/PL3840767T3/pl unknown
- 2020-05-28 MX MX2021014497A patent/MX2021014497A/es unknown
- 2020-05-28 SG SG11202113125QA patent/SG11202113125QA/en unknown
- 2020-05-28 SI SI202030322T patent/SI3840767T1/sl unknown
-
2021
- 2021-11-25 IL IL288412A patent/IL288412A/en unknown
- 2021-12-22 CO CONC2021/0017664A patent/CO2021017664A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3840767T (lt) | 2024-02-26 |
| BR112021023957A2 (pt) | 2022-02-01 |
| SG11202113125QA (en) | 2021-12-30 |
| HRP20240017T1 (hr) | 2024-04-26 |
| IL288412A (en) | 2022-01-01 |
| ES2970223T3 (es) | 2024-05-27 |
| PL3840767T3 (pl) | 2024-03-04 |
| CN113891723A (zh) | 2022-01-04 |
| WO2020239937A1 (en) | 2020-12-03 |
| EP3840767A1 (en) | 2021-06-30 |
| EP4276463A2 (en) | 2023-11-15 |
| KR20220012938A (ko) | 2022-02-04 |
| CA3141951A1 (en) | 2020-12-03 |
| EP3840767B1 (en) | 2023-11-15 |
| US20220213170A1 (en) | 2022-07-07 |
| CO2021017664A2 (es) | 2022-01-17 |
| SI3840767T1 (sl) | 2024-04-30 |
| JP2022535784A (ja) | 2022-08-10 |
| PT3840767T (pt) | 2024-01-29 |
| DK3840767T3 (da) | 2024-02-12 |
| FI3840767T3 (fi) | 2024-01-31 |
| EP4276463A3 (en) | 2024-01-10 |
| AU2020281912A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014497A (es) | Peptidos. | |
| Villanueva et al. | Efficiency of MHC class I antigen processing: a quantitative analysis | |
| NZ570553A (en) | Immunogenic peptide sequences from influenza A and B and uses thereof for vaccines | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| NZ601868A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| WO2018067217A3 (en) | COMPOSITIONS COMPRISING SHORT PEPTIDES DERIVED FROM PEDF AND USES THEREOF | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| PH12021550030A1 (en) | Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| MX2020010806A (es) | Peptidos anti-inflamatorios y usos de los mismos. | |
| NZ609916A (en) | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof | |
| EP2589658A4 (en) | PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN | |
| NZ703514A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| RU2010154101A (ru) | Пептиды эпитопов mybl2 и содержащие их вакцины | |
| MX2021003109A (es) | Proteina para el tratamiento de enfermedades inflamatorias. | |
| WO2019094938A3 (en) | Methods and compositions for the treatment of wounds | |
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| MX2022014649A (es) | Coctel de peptidos. | |
| RU2020106669A (ru) | Синтетические белки и пути их терапевтического применения | |
| PH12018500468A1 (en) | Fusion protein | |
| UA83989C2 (ru) | Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение | |
| MX2020013569A (es) | Proteína novedosa con propiedades antiinflamatorias. | |
| NZ597470A (en) | Therapeutic peptides, polypeptides ans nucleic acid sequences | |
| MX2020007336A (es) | Metodos y composiciones para modular la disfuncion de celulas endoteliales. |